ImmunityBio, Inc.

How big is ImmunityBio, Inc.?

As of Jun 18, ImmunityBio, Inc. has a market capitalization of $2.51 billion, with net sales of $31.23 million and a net profit of -$409.18 million over the last four quarters. The company's shareholder's funds are -$489.10 million, and total assets are $382.93 million.

Market Cap: As of Jun 18, ImmunityBio, Inc. has a market capitalization of 2,507.11 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, ImmunityBio reported net sales of 31.23 million and a net profit of -409.18 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to -489.10 million, while total assets were reported at 382.93 million.

What does ImmunityBio, Inc. do?

ImmunityBio, Inc. is a clinical-stage immunotherapy company focused on utilizing the innate immune system to treat cancer and other diseases. As of March 2025, it reported net sales of $17 million and a net loss of $130 million, with a market cap of approximately $2.51 billion.

Overview:<BR>ImmunityBio, Inc. is a clinical-stage immunotherapy company focused on harnessing the innate immune system, particularly natural killer cells, to treat cancer, infectious diseases, and inflammatory diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 17 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -130 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2,507.11 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.23 <BR>Return on Equity: 76.39% <BR>Price to Book: -4.24<BR><BR>Contact Details:<BR>Address: 3530 John Hopkins Ct, SAN DIEGO CA: 92121-1121 <BR>Tel: 1 858 6330300 <BR>Fax: 1 302 6745266 <BR>Website: https://www.nantkwest.com/

Should I buy, sell or hold ImmunityBio, Inc.?

Who are in the management team of ImmunityBio, Inc.?

As of March 2022, the management team of ImmunityBio, Inc. includes Dr. Patrick Soon-Shiong (Executive Chairman), Dr. Barry Simon (President and Chief Administrative Officer), Mr. Frederick Driscoll (Lead Independent Director), and several other directors. This team is responsible for the company's strategic direction and operations.

As of March 2022, the management team of ImmunityBio, Inc. includes the following individuals:<BR><BR>- Dr. Patrick Soon-Shiong, who serves as the Executive Chairman of the Board.<BR>- Dr. Barry Simon, who is the President, Chief Administrative Officer, and a Director.<BR>- Mr. Frederick Driscoll, who holds the position of Lead Independent Director.<BR>- Ms. Cheryl Cohen, who is a Director.<BR>- Mr. Michael Blaszyk, who serves as an Independent Director.<BR>- Mr. John Thomas, who is also an Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Is ImmunityBio, Inc. overvalued or undervalued?

As of August 12, 2024, ImmunityBio, Inc. is rated as "risky" and overvalued, with negative financial metrics such as a Price to Book Value of -4.70 and a P/E ratio of -5.48, despite a recent short-term gain of 10.04%, contrasting sharply with its long-term 5-year return of -66.43%.

As of 12 August 2024, ImmunityBio, Inc. has moved from a grade of "does not qualify" to "risky." The company is considered overvalued based on its current financial metrics. Key valuation ratios include a Price to Book Value of -4.70, an EV to EBIT of -11.19, and an EV to EBITDA of -11.83, all indicating significant financial distress and negative performance relative to its assets and earnings.<BR><BR>In comparison to peers, ImmunityBio's P/E ratio is -5.48, while TG Therapeutics, Inc. is very expensive with a P/E of 83.91, and Mirum Pharmaceuticals, Inc. also carries a risky designation with a P/E of -66.39. This highlights the challenges ImmunityBio faces in the market. Despite a recent 1-week return of 10.04% compared to the S&P 500's 1.05%, the longer-term performance shows a stark contrast, with a 5-year return of -66.43% against the S&P 500's 96.61%, reinforcing the notion that the stock is overvalued.

Is ImmunityBio, Inc. technically bullish or bearish?

As of October 24, 2025, ImmunityBio, Inc. has shifted to a mildly bearish trend, with mixed technical indicators and significant underperformance against the S&P 500, showing a 1-year return of -41.33% compared to the index's 16.90%.

As of 24 October 2025, the technical trend for ImmunityBio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on the weekly timeframe but bearish on the monthly, while the RSI is bullish weekly but shows no signal monthly. Bollinger Bands and KST indicate a bearish outlook on both weekly and monthly periods. Moving averages are bearish on the daily timeframe, and Dow Theory reflects a mildly bearish stance weekly with no trend monthly. <BR><BR>In terms of performance, the stock has underperformed against the S&P 500 across multiple periods, with a 1-year return of -41.33% compared to the S&P 500's 16.90%, and a 5-year return of -71.21% versus 95.99% for the index.